Research

Hormonal

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce liver fat content in patients with NAFLD, as assessed by MRI-based techniques.

SGLT2 inhibitors like empagliflozin or dapagliflozin reduce liver fat in people with type 2 diabetes and fatty liver. They are oral medications taken daily. They can increase the risk of genital infections, so good hygiene is important. They also help with weight and blood sugar.

GoodSupportsHIGH confidence
SGLT2 inhibitors (mostly empagliflozin and dapagliflozin) reduced liver fat content, as assessed by magnetic resonance-based techniques.
Peter Y. W. Chan et al. · JBJS Reviews · 2024

Why this rating

Based on 7 RCTs included in the review.

Source

Glucagon-like Peptide-1 Agonists

Peter Y. W. Chan et al. · JBJS Reviews · 2024

DOI 10.2106/jbjs.rvw.23.00167

systematic_review · n=2597Cited 14×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →